ProShares Ultra Health Care (RXL)

RXL does for healthcare bulls what leverage does for any bet: it amplifies. The NASDAQ Health Care Index moves up one percent, RXL aims to move up three. It’s a tactical instrument, not a pension-fund holding, because of how leverage compounds daily.

The fund wraps healthcare sector bets in leverage. Its underlying index — the NASDAQ Health Care Index — is large, covering the full breadth of healthcare: integrated pharmaceutical firms, biotech single-shots, medical device makers, health insurers, hospital operators, diagnostic-equipment manufacturers. Names like Novo Nordisk, Regeneron, Amgen, Broadcom (via its medical-tech division), and a long tail of smaller innovators. ProShares takes that index and applies a three-to-one multiplier each trading day.

Mechanics matter here. ProShares holds healthcare stocks and derivatives (futures, swaps) engineered to move three times the index. Every night at close, the fund rebalances, recalibrating the hedge ratio so the next day’s move is again three times. That daily reset is the feature that lets leveraged funds promise consistent amplification. It’s also the reason volatility decay is so punishing.

A quick scenario: suppose the healthcare index falls hard one day (five percent), then rallies hard the next (five percent gain). It’s flat over two days. An unleveraged holder broke even. A 3x long holder? Down nine percent the first day (three times the five percent loss), up fifteen percent the second (three times the five percent gain). Overall? Negative. The math of compounded daily losses and gains guarantees that, over time, a fund that swings up and down loses money to volatility, not direction.

Healthcare stock prices do move in patterns that sometimes favor tactical traders. A regulatory decision — a drug approval, a patent ruling, a new reimbursement rule — can whip the sector sharply in a day or week. A trader convinced healthcare is about to pop on better-than-expected Phase 3 trial data, or on Medicare announcement of improved Alzheimer’s coverage, might own RXL for days or weeks around that event. But extending the hold past the trigger move becomes increasingly risky.

The fund charges roughly one percent per year in expenses, which is standard for leveraged ProShares products. Combined with the cost of holding swap contracts and rebalancing daily, the drag compounds. Over a year, a static healthcare sector barely moving would cost RXL roughly one percent to fees, plus whatever decay the daily rebalancing inflicts.

Price action tells the real story. RXL is less liquid than its inverse cousin (fewer traders betting long leverage on a daily reset) but still has measurable daily volume and tight bid-ask. Over very short holds — hours or a few days — the spreads are navigable. Over months or years, the friction and decay usually overwhelm the leverage benefit.

The true healthcare sector risks — pipeline failures, pricing pressure from regulators, patent cliffs, clinical trial disappointments — are all amplified threefold inside RXL. A pharma company’s late-stage trial failure that drops the sector two percent spikes RXL down six percent. That can be catastrophic if the entire sector rotates on bad news; leverage turns a digestible loss into a portfolio-denting one.

Anyone using RXL should understand they are not owning healthcare for the long term. They are timing a sector move they believe is imminent. If the move doesn’t arrive soon, they should sell before decay consumes the position. If the conviction is more than a few months old and the trigger has not yet fired, the bet has probably already lost money, because the daily volatility and rebalancing drag will have nibbled away returns faster than the underlying sector can deliver alpha.